HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. - Wikidata - awgldk - TriplyDB

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

http://www.wikidata.org/entity/Q34974436

about

Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers MLK3 Signaling in Cancer Invasion Aberrant Splicing of Estrogen Receptor, HER2, and CD44 Genes in Breast Cancer Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics Investigating intratumour heterogeneity by single-cell sequencing Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence.Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention Developmental therapeutics for inflammatory breast cancer: Biology and translational directions Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery.Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy.Prognostic Value of Her2/neu Expression in Gastrointestinal Stromal Tumors: Immunohistochemical Study.Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathways Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models.Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin.Identification of mTORC2 as a necessary component of HRG/ErbB2-dependent cellular transformation Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines Therapeutic targeting of integrin αvβ6 in breast cancer.Intratumoral heterogeneity impacts the response to anti-neu antibody therapy.AKT regulates NPM dependent ARF localization and p53mut stability in tumors.The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.Enhanced breast cancer therapy with nsPEFs and low concentrations of gemcitabine.Resistance to HER2-targeted therapies: a potential role for FOXM1.Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK HER2 in solid tumors: more than 10 years under the microscope; where are we now?HER2-directed therapy: current treatment options for HER2-positive breast cancer.Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer.Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.Efficacy and tolerability of lapatinib in the management of breast cancer Trastuzumab: updated mechanisms of action and resistance in breast cancer Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.Polymeric oncolytic adenovirus for cancer gene therapy.Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.

P2860

Q21132473-19DCA828-3384-44B4-8348-A1903874A31A Q24303562-B11973AD-E244-4466-B215-88DF9167BF13 Q26746892-183FA3C7-1CC5-4812-87CB-13B5AF129E67 Q26773907-E8DDF972-B973-4388-973B-2E57248FF048 Q26780335-B02CF067-F2F6-443F-82A0-4628987686B8 Q27015460-C3708FA0-8FF2-4633-8E91-2613B501843D Q27851725-74F7FC51-9924-4ADD-B594-1EC522A3B6E3 Q28067145-2FC06789-1B51-4F64-8675-B6A2D34CDF47 Q28075322-94A4C874-5E47-4D45-B4C0-67DB4E4C1EF2 Q31038214-178093D0-CA1D-424F-95F3-340EDAE5753B Q33555302-39BFBD60-4900-44B3-B71E-4777551F4E3C Q33565890-A9DF49C5-1C18-4028-82D2-B944380E5EC9 Q33584432-ED25653C-BA05-48EB-8D5A-8292E4773DF0 Q33648150-93C58036-0836-4724-9AB2-3F641C8B7E49 Q33682910-0484AEF8-6C33-4467-AC04-B692465D7623 Q33703311-6BB89679-DEA7-4971-B4FD-A5D146EF03F0 Q33744198-D15009A4-15AE-46E0-83F2-6BC7D9E20031 Q33758255-D4087223-8A8A-4C0B-B154-5DC869EC2353 Q33822560-8BF56327-C85C-4F51-901F-D33F6F969D21 Q34120685-1F830CBF-2A0C-413E-8ADB-CD3A4AFABDF0 Q34169228-8A723613-E0AB-413A-B22A-12930925D31B Q34227622-5DEA2D87-2257-4BFC-B47E-A417C67845B9 Q34373936-E8683561-4E3C-41E8-B3D0-14D455A2730F Q34402129-86CCCA47-A7D1-4088-AA29-536D2DB7F86A Q34955355-7F7AE2E3-5C34-4002-9A90-E838E826794D Q35036012-460D033E-68E8-4E6E-86BE-F372AC5CA9F2 Q35211263-A7083AA0-1EDC-4234-90EE-70D31C3A004F Q35551522-BE4F6C99-73D8-4F31-B2FC-ABAB28784E5E Q35606679-8AC9312A-A42B-4FF9-AA19-80C68148F608 Q35624809-72BF5265-EF77-4BEB-8C8D-B1496C66BF95 Q35749122-D463F8D0-5F4A-4A93-8CDD-261888B74A1C Q35793883-14FE82D8-5205-4CB8-9445-D3B864D4CDF4 Q35835926-53DB4B1C-5228-477C-8C15-A43B113F92C6 Q36036437-D0570BC0-4B8B-4B9E-BC69-BF2970CD4595 Q36108820-56588F13-9E01-4B48-8D09-8D6A4DEE55D5 Q36172627-05FFCBC4-0EAD-4A34-AFEA-60803257A277 Q36303278-108D2C0C-59FC-4D67-96F6-8FE0F585E624 Q36331722-88A373E6-BE9B-4DEE-9867-EA527A62D211 Q36344901-01F764BC-3682-4ECE-B39C-EDE711F10E8E Q36401731-E94229B5-599E-409E-BAF6-AB9571EA15A8

P2860

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

http://www.wikidata.org/entity/Q34974436

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

HER2-amplified breast cancer: ...... and novel targeted therapies.

@ast

HER2-amplified breast cancer: ...... and novel targeted therapies.

@en

HER2-amplified breast cancer: ...... and novel targeted therapies.

@nl

type

label

HER2-amplified breast cancer: ...... and novel targeted therapies.

@ast

HER2-amplified breast cancer: ...... and novel targeted therapies.

@en

HER2-amplified breast cancer: ...... and novel targeted therapies.

@nl

prefLabel

HER2-amplified breast cancer: ...... and novel targeted therapies.

@ast

HER2-amplified breast cancer: ...... and novel targeted therapies.

@en

HER2-amplified breast cancer: ...... and novel targeted therapies.

@nl

P1433

Q34974436-9983201B-CECE-4B9A-9906-C4E21AFB4E40

P1476

Q34974436-1C99A9E8-40B5-4D98-B75A-F35BAFF39B37

P2093

Q34974436-4B6C5228-1FEF-4872-AF11-48F604A1626D

Q34974436-71D10FF2-3F69-4EC8-B2B9-4007B0ADF7FC

P2860

Q34974436-0086ADD6-0D5F-4744-ABCC-8A3C792BD222

Q34974436-00A1CB2D-A9E4-456E-813E-C7A19A365772

Q34974436-0684A406-D4EB-46D7-8104-0370DEEB2858

Q34974436-06E268DE-970C-4B3C-B312-DFB8E9E9F041

Q34974436-0782950B-B86F-4ECA-A2D7-50D0FE645711

Q34974436-0B0A031A-A3BE-4214-BD22-E3AB0F951C90

Q34974436-0D50F15A-D0A8-40B5-85E1-5EB45A6A4187

Q34974436-0D657983-FA28-45AC-BA5B-1C385C0B5CCB

Q34974436-0E84EB40-0E99-4A45-AF6C-B1EB6CAA1B2C

Q34974436-18ED1200-D0EC-43C9-858E-3E11B6AA01BA

P304

Q34974436-65E2A4B6-557F-4A11-A9B8-2F98DC82E0EE

P31

Q34974436-6685FE23-ECF3-403B-B8F4-9617EB2BD625

P356

Q34974436-7FCF86EC-5C3D-4F0A-91AA-ED2CBFC4A7FC

P433

Q34974436-63E81742-4648-4467-8C1E-22E306EDF949

P478

Q34974436-2629089B-C065-4B96-8E88-31F1D9A59EE8

P577

Q34974436-DC2826CA-C437-47AF-A3E2-8735E695D55E

P5875

Q34974436-069ABD2C-870C-4F74-8694-F03B4FD10CD5

P698

Q34974436-6E27892F-083D-4F3E-9C2A-3731ECE9DAE9

P932

Q34974436-D04637E4-D2CD-466E-B2E1-0249644D170D

P356

P1433

Expert Review of Anticancer Therapy

P1476

HER2-amplified breast cancer: ...... and novel targeted therapies.

@en

P2093

Devika Gajria

http://www.w3.org/2001/XMLSchema#string

Sarat Chandarlapaty

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

P304

263-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.10.226

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49855977

http://www.w3.org/2001/XMLSchema#string

P698

21342044

http://www.w3.org/2001/XMLSchema#string

P932

3092522

http://www.w3.org/2001/XMLSchema#string